Monocyte-driven atypical cytokine storm and aberrant neutrophil activation as key mediators of COVID-19 disease severity

Lore Vanderbeke, Pierre Van Mol, Yannick Van Herck, +52

Nature Communications

Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases

Erwin Dreesen, Bram Verstockt, Sumin Bian, +8

Clinical Gastroenterology and Hepatology

InflammationSupport MonitoringFunctional Gastrointestinal DisorderAllergyMucosal Immunology +7

Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates

Bram Verstockt, Erwin Dreesen, Maja Noman, +8

Journal of Crohn s and Colitis

Software Tools for Model-Informed Precision Dosing: How Well Do They Satisfy the Needs?

Wannee Kantasiripitak, Ruth Van Daele, Matthias Gijsen, +3

Frontiers in Pharmacology

EngineeringSoftware ToolsPharmacotherapyPharmacodynamic ModelingSystems Pharmacology +30

Monitoring a Combination of Calprotectin and Infliximab Identifies Patients With Mucosal Healing of Crohn’s Disease

Erwin Dreesen, Filip Baert, David Laharie, +12

Clinical Gastroenterology and Hepatology

InflammationChronic Inflammatory DiseasesMucosal HealingMucosal ImmunologyCrohn ’ +5

Variability in Golimumab Exposure: A ‘Real-Life’ Observational Study in Active Ulcerative Colitis

Iris Detrez, Erwin Dreesen, Thomas Van Stappen, +6

Journal of Crohn s and Colitis

A Genetic Variation in the Neonatal Fc-Receptor Affects Anti-TNF Drug Concentrations in Inflammatory Bowel Disease

Thomas Billiet, Erwin Dreesen, Isabelle Cleynen, +5

The American Journal of Gastroenterology

Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease

Karen van Hoeve, Erwin Dreesen, Ilse Hoffman, +4

Journal of Crohn s and Colitis

Peak Concentrations of Ustekinumab After Intravenous Induction Therapy Identify Patients With Crohn’s Disease Likely to Achieve Endoscopic and Biochemical Remission

Jurij Hanžel, Jurij Zdovc, Tina Kurent, +12

Clinical Gastroenterology and Hepatology

ImmunologyGastroenterologyBiochemical RemissionAchieve EndoscopicClinical Gastroenterology +3

Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples

Ann Gils, Thomas Van Stappen, Erwin Dreesen, +3

Inflammatory Bowel Diseases